Physician profile
Jesse Richards
NPI 1598112823
$279,233.76
in general payments reported to CMS, 2019-2025
5 companies · $132K in 2025
The $132K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $9,397 · 2023: $16K · 2024: $122K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $199K · Consulting Fee: $23K · Travel and Lodging: $23K · Honoraria: $18K · Food and Beverage: $4,696 · Education: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199,008.64 |
| Consulting Fee | $23,389.50 |
| Travel and Lodging | $22,877.01 |
| Honoraria | $18,256.79 |
| Food and Beverage | $4,695.67 |
| Education | $1,372.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179,597.65 | 2022-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $66,156.35 | 2021-2025 | Wegovy, Ozempic |
| Rhythm Pharmaceuticals, INC. | $24,106.66 | 2022-2025 | Imcivree, Imcivree |
| Novo Nordisk As | $8,323.10 | 2025 | |
| Eli Lilly and Company | $1,050.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.